Vasoconstrictive Properties of the 5HT 1B/1D Agonists: Response to Dahlöf and Mathew

Dahlöf CGH Mathew N Cardiovascular safety of 5HT1B/1D agonists—Is there a cause for concern? Cephalalgia 1998; 18: 532–8

Dahlöf CGH Falk L Risenfors M Lewis CP Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/ or pain in the chest, neck, and/or throat following sumatriptan. Cephalalgia 1998; 18: 546–51

Freedom of Information. Sumatriptan Adverse Event Reporting, United States Food and Drug Administration

Rosenthal S Chen R The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Publ Health 1995; 85: 1706–9

Swan L Bimie DH Hood S The effects of subcutaneous naratriptan 1.5 mg on the systemic, pulmonary, and coronary circulation in patients with suspected coronary artery disease. Cephalalgia 1997; 17: 428

Summary Basis of Approval, Naratriptan NDA 20-763, United States Food and Drug Administration, 1998

MacIntyre PD Bhargava B Hogg KJ Gemmill JD Hillis WS Effect of i.v. sumatriptan, a selective 5HT1 agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992; 54: 541–6

MacIntyre PD Bhargava B Hogg KJ Gemmill JD Hillis WS Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993; 87: 401–5

Summary Basis of Approval, Zolmitriptan NDA 20-768, United States Food and Drug Administration, 1997